Institute of Tropical Medicine and International Health, Charité - University Medical School Berlin, Spandauer Damm 130, 14050 Berlin, Germany.
Acta Trop. 2010 Apr;114(1):63-6. doi: 10.1016/j.actatropica.2009.12.008. Epub 2010 Jan 7.
In 111 children under five years of age and with uncomplicated malaria in Nouna, north-western Burkina Faso, amodiaquine treatment failed in 75% (after PCR-based exclusion of new infections, 32%). In these, we assessed the role of Plasmodium falciparum pfmdr1 and pfcrt polymorphisms in amodiaquine resistance. Except for pfmdr1 1246Y (prevalence, 5%), no P. falciparum allele predicted treatment outcome. Pfcrt 76T as well as pfmdr1 86Y, 86Y-184F-1246D, and 86Y-184Y-1246Y were positively selected in treatment failures, and pfmdr1 86N-184F-1246D negatively. The weak association of pfmdr1/pfcrt alleles with amodiaquine treatment outcome suggests further factors to be involved in the unsatisfactory low efficacy of the drug and limits the usefulness of these markers in this area.
在布基纳法索西北部努纳的 111 名五岁以下患有单纯性疟疾的儿童中,氨苯砜治疗失败了 75%(基于 PCR 的新感染排除后,32%)。在这些患者中,我们评估了疟原虫 pfmdr1 和 pfcrt 多态性在氨苯砜耐药中的作用。除了 pfmdr1 1246Y(流行率为 5%)外,没有疟原虫等位基因预测治疗结果。Pfcrt 76T 以及 pfmdr1 86Y、86Y-184F-1246D 和 86Y-184Y-1246Y 在治疗失败中被正向选择,而 pfmdr1 86N-184F-1246D 则被负向选择。pfmdr1/pfcrt 等位基因与氨苯砜治疗结果的弱相关性表明,还有其他因素参与了药物疗效不理想的情况,这限制了这些标记物在该地区的实用性。